OmniAb to Participate in Upcoming Investor Conferences in May
April 25 2023 - 7:00AM
Business Wire
OmniAb, Inc. (NASDAQ: OABI) today announced that
management will be participating in five upcoming investor
conferences in May.
- H.C. Wainwright BioConnect Investor Conference at NASDAQ,
May 2, 2023 at Nasdaq World Headquarters, New York City.
Management will be participating in a fireside chat on Tuesday, May
2nd at 9:30 a.m. Eastern time and will be hosting one-on-one
meetings with investors.
- Inaugural E.F. Hutton Global Conference, May 10-11,
2023 at The Plaza Hotel, New York City. Management will be
hosting one-on-one meetings with investors on May 11.
- Benchmark 3rd Annual Virtual Healthcare House Call 1x1
Investor Conference, May 23, 2023. Management will be hosting
virtual one-on-one meetings with investors.
- B. Riley Securities 23rd Annual Institutional Investor
Conference, May 24-25, 2023 at The Beverly Hilton, Beverly
Hills. Management will be hosting one-on-one meetings with
investors on May 24.
- Craig-Hallum 20th Annual Institutional Investor
Conference, May 31, 2023 at The Depot Renaissance
Minneapolis Hotel, Minneapolis. Management will be hosting
one-on-one meetings with investors.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that
have been genetically modified to generate antibodies with human
sequences to facilitate development of human therapeutic
candidates. OmniFlic® (transgenic rat) and OmniClic®
(transgenic chicken) address industry needs for bispecific antibody
applications though a common light chain approach, and OmniTaur™
features unique structural attributes of cow antibodies for complex
targets. We believe the OmniAb animals comprise the most diverse
host systems available in the industry and they are optimally
leveraged through computational antigen design and immunization
methods, paired with high-throughput single B cell phenotypic
screening and mining of next-generation sequencing datasets with
custom algorithms to identify fully human antibodies with superior
performance and developability characteristics. An established core
competency focused on ion channels and transporters further
differentiates our technology and creates opportunities in emerging
target classes. OmniAb antibodies have been leveraged across
modalities, including bispecific antibodies, antibody-drug
conjugates and others. The OmniAb suite of technologies span from
BI-powered repertoire generation to cutting edge antibody discovery
and optimization offering a highly efficient and customizable
end-to-end solution for the growing discovery needs of the global
pharmaceutical industry.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230425005012/en/
OmniAb, Inc. Neha Singh investors@OmniAb.com Twitter @OmniAbTech
(510) 768-7760
LHA Investor Relations Yvonne Briggs ybriggs@lhai.com (310)
691-7100
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Sep 2024 to Oct 2024
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Oct 2023 to Oct 2024